Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from a sex-specific analysis of 160 real-world ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Liz Wood, who lives in Beacon, is the founder of The MYT1L Project ( myraregene.org ), a foundation that supports families whose children are affected by a rare genetic disorder.

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Peter Monteleone will present data from a sex-specific ...